Robert A. Hutchinson
Direttore/Membro del Consiglio presso SYNCONA LIMITED
Patrimonio netto: 148 897 $ in data 30/04/2024
Provenienza dei contatti di primo grado di Robert A. Hutchinson
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
Mutual Fd-Closed End | Investment Trusts/Mutual Funds | 20 | |
Public Company | Financial Conglomerates | 18 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Robert A. Hutchinson tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
Columbia Threadneedle Asset Managers Ltd.
Columbia Threadneedle Asset Managers Ltd. Investment ManagersFinance Columbia Threadneedle Asset Managers Ltd. (CTAM) is an asset management firm headquartered in London, UK. The firm was founded in 1990 as F&C Asset Managers Ltd. and renamed BMO Asset Managers Ltd. in 2018. They changed their name to Columbia Threadneedle Asset Managers Ltd. when BMO rebranded to Columbia Threadneedle Investments in 2022. The firm is a subsidiary of Columbia Threadneedle AM (Holdings) Plc, ultimately held by Ameriprise Financial, Inc. (NYSE: AMP) in the US. CTAM manages a range of in-house and multi-manager funds for private individuals and institutional clients. | Investment Managers | Head-Equity Investments | |
UBS | Investment Managers | Corporate Officer/Principal | |
TRANSLATE BIO, INC. | Biotechnology | Director/Board Member | |
ABERDEEN ASSET MANAGEMENT | Investment Managers | Director/Board Member | |
THE WEIR GROUP PLC | Trucks/Construction/Farm Machinery | Director/Board Member | |
HARGREAVES LANSDOWN PLC | Investment Managers | Director/Board Member Founder | |
University of Cambridge | College/University | Undergraduate Degree Doctorate Degree | |
University of Bristol | College/University | Graduate Degree Undergraduate Degree | |
Aveni SA
Aveni SA Chemicals: Major DiversifiedProcess Industries Aveni SA designs, develops, manufactures and markets chemical formulations. It enables future technologies with its approach to metallization for semiconductor, MEMS, advanced packaging, and flex applications. The company was founded in 2001 and is headquartered in Massy, France. | Chemicals: Major Diversified | Director/Board Member | |
University of Leiden | College/University | Graduate Degree | |
Bird Rock Bio, Inc.
Bird Rock Bio, Inc. BiotechnologyHealth Technology Bird Rock Bio, Inc. develops protein therapeutics. It focuses on the discovery and development of novel antibodies with upsized potential that represent to antibody therapeutics. The company was founded by Richard J. Ulevitch, Phyllis Ellen Whiteley and Katherine S. Bowdish in 2007 and is headquartered in La Jolla, CA. | Biotechnology | Director/Board Member | |
Canbex Therapeutics Ltd.
Canbex Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Canbex Therapeutics Ltd. engages in the development of novel peripherally-acting cannabinoid agonists and mimetics for the treatment of multiple sclerosis spasticity and pain. Its lead drug candidate, VSN 16, has been established as a potent, stable and orally-available agonist of GPR-55 with a clear anti-spasticity effect in a validated preclinical model. The company was founded by David Baker, Gavin Giovannoni, Cristina Visintin, Gareth Pryce and David Lawrence Selwood in 2005 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Standard Life Investments (Holdings) Ltd.
Standard Life Investments (Holdings) Ltd. Investment ManagersFinance Part of abrdn Plc, Standard Life Investments (Holdings) Ltd. is a British company that provides asset management services. The company is based in Lothian, UK. | Investment Managers | Director/Board Member Director/Board Member | |
INKEF Capital BV
INKEF Capital BV Investment ManagersFinance INKEF Capital BV is an Independent Venture Capital firm founded in 2010 by Frank R Landsberger. INKEF Capital BV is headquartered in Amsterdam. | Investment Managers | Private Equity Investor | |
The Syncona Foundation | Investment Trusts/Mutual Funds | Director/Board Member Director/Board Member | |
Asceneuron SA
Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | Pharmaceuticals: Major | Chairman | |
Ravenscroft (CI) Ltd.
Ravenscroft (CI) Ltd. Investment Banks/BrokersFinance Ravenscroft (CI) Ltd. provides management consultancy services other than financial management. The company was founded by Jonathan Richard Ravenscroft and Andrew Marshall Stewart on March 8, 2005 and is headquartered in St. Peter Port, the United Kingdom. | Investment Banks/Brokers | Chairman Corporate Officer/Principal Corporate Secretary Director/Board Member Director/Board Member Director of Finance/CFO Chief Operating Officer Human Resources Officer Public Communications Contact Compliance Officer | |
T1D Exchange
T1D Exchange Pharmaceuticals: MajorHealth Technology T1D Exchange is a nonprofit organization that was established in 2010 with initial and ongoing support from the Leona M. and Harry B. Helmsley Charitable Trust. T1D Exchange is based in Boston, MA. The non-profit company is dedicated to improving outcomes for the entire T1D population through real-world evidence and clinical data collection and analysis. T1D Exchange is a leading provider of real-world evidence, identifying gaps in data and redefining best practices to improve the lives of those living with T1D. The company actively supports quality improvement and innovation through its quality improvement collaborative, patient registry, and data-oriented research services. David Walton has been the CEO of the company since 2018. | Pharmaceuticals: Major | Director/Board Member | |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Investment Managers | Private Equity Investor Private Equity Investor Director of Finance/CFO Director/Board Member Private Equity Investor Private Equity Investor | |
Aalto University School of Business | College/University | Masters Business Admin | |
Forendo Pharma Oy
Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland. | Pharmaceuticals: Major | Chairman | |
Metabomed Ltd.
Metabomed Ltd. Pharmaceuticals: MajorHealth Technology Metabomed Ltd. operates as a drug discovery company. It focuses in the field of cancer metabolism with a proprietary target identification platform based on computational biology and metabolomics. The company was founded by Eytan Ruppin, Tomer Shlomi and Eyal Gottlieb in 2013 and is headquartered in Yavne, Israel. | Pharmaceuticals: Major | Director/Board Member | |
Calypso Biotech SA
Calypso Biotech SA Pharmaceuticals: MajorHealth Technology Calypso Biotech SA operates as a innovative biopharmaceutical company for gastrointestinal immunological disorders. The company was founded by Alain Vicari and Yolande Chvatchko in 2013 and is headquartered in Plan-les-Ouates, Germany. | Pharmaceuticals: Major | Director/Board Member | |
Padlock Therapeutics, Inc.
Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member | |
Onward Medical SA
Onward Medical SA BiotechnologyHealth Technology ONWARD Inc develops medical devices. It also provides stimulation system to rehabilitate individuals with spinal cord injury. The company was founded by Jocelyn Bloch, Sjaak Deckers, Grégoire Courtine, and Vincent Delattre in December 2014 and is headquartered in Lausanne, Switzerland. | Biotechnology | Director/Board Member | |
NMD Pharma A/S
NMD Pharma A/S BiotechnologyHealth Technology NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark. | Biotechnology | Director/Board Member | |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | Investment Managers | Private Equity Investor | |
Varmx BV
Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Biotechnology | Director/Board Member | |
Scenic Biotech BV
Scenic Biotech BV Miscellaneous Commercial ServicesCommercial Services Scenic Biotech BV is using genomics to develop innovative therapies for patients affected by severe diseases. The company was founded by Thijn Brummelkamp and Sebastian Nijman and is headquartered in Amsterdam, Netherlands. | Miscellaneous Commercial Services | Director/Board Member | |
iOnctura SA
iOnctura SA Miscellaneous Commercial ServicesCommercial Services iOnctura SA is a pre-clinical stage biopharmaceutical company focused on the research and development of novel immuno-oncology therapeutics for patients fighting cancer. The company was founded in June 2017 and is headquartered in Geneve, Switzerland. | Miscellaneous Commercial Services | Director/Board Member | |
Syncona Investment Management Ltd.
Syncona Investment Management Ltd. Investment ManagersFinance Syncona Investment Management Ltd. (Syncona) is the asset management subsidiary of Syncona Ltd. in Great Britain. Headquartered in London, the firm was co-founded by Martin Murphy alongside The Wellcome Trust. Syncona is focused on founding, building and funding a portfolio of global leaders in life science. | Investment Managers | Chairman Director of Finance/CFO Head-Equity Investments | |
DNA Script SAS
DNA Script SAS Medical SpecialtiesHealth Technology DNA Script engages in the provision of research and development in biotechnology. It manufactures synthetic deoxyribonucleic acid using enzymatic technology. The company was founded by Thomas Ybert, Sylvain Gariel and Xavier Godron in 2014 and is headquartered in Paris, France. | Medical Specialties | Director/Board Member | |
Syncona GP Ltd. | Director/Board Member Director/Board Member | ||
Ravenscroft Ltd. (Private Equity)
Ravenscroft Ltd. (Private Equity) Investment ManagersFinance Ravenscroft Ltd. (Private Equity) is an independent private equity subsidiary of Ravenscroft Ltd. founded in 2005. The firm is headquartered in St. Peter Port. | Investment Managers | Chief Investment Officer Private Equity Investor General Counsel Compliance Officer Private Equity Investor Director of Finance/CFO Private Equity Investor Human Resources Officer Compliance Officer Compliance Officer | |
QurAlis Corp.
QurAlis Corp. Pharmaceuticals: MajorHealth Technology QurAlis Corp. engages in discovering and developing new therapies for amyotrophic lateral sclerosis and other neurological diseases. It offers therapeutic programs and targets, and biomarkers. The company was founded by Clifford Woolf, Kevin Eggan, Jonathan J. Fleming, and Kasper Roet and is headquartered in North Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member | |
Salvia BioElectronics BV
Salvia BioElectronics BV BiotechnologyHealth Technology Salvia BioElectronics BV develops a bioelectronics therapy for people suffering from chronic neurological diseases. The company was founded by Sjaak Deckers and Hubert Martens in 2017 and is headquartered in Eindhoven, the Netherlands. | Biotechnology | Director/Board Member | |
Caraway Therapeutics, Inc.
Caraway Therapeutics, Inc. BiotechnologyHealth Technology Caraway Therapeutics, Inc. provides heathcare services. The company was founded by Timothy Harris, Wade Harper ,Ivan Dikic ,Tony Hyman and is headquartered in Cambridge, MA. | Biotechnology | Chairman | |
Comet Therapeutics, Inc.
Comet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Comet Therapeutics, Inc. develops and commercializes treatments for patients suffering from metabolic, neurological and immunological disorders. The company was founded by Angellina Sekirnik and Enej Kuscer in 2008 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member | |
Ridgeway Partners Holdings Ltd.
Ridgeway Partners Holdings Ltd. Financial ConglomeratesFinance Part of Teneo Holdings LLC, Ridgeway Partners Holdings Ltd. is a 25-person executive search firm with offices in multiple locations. The company is based in London, UK. Ridgeway Partners differentiates itself with its creativity, tenacity, responsiveness, and unparalleled track record of success. The British company has built long-standing relationships with its clients because of its exclusivity, responsiveness, discretion, and track record of success. Founded in 2016, the company specializes in executive search, board appointments, and succession planning for a select group of multi-sector, domestic and international companies. Ridgeway Partners was acquired by Teneo Holdings LLC on January 04, 2021. | Financial Conglomerates | Director/Board Member | |
Draupnir Bio ApS
Draupnir Bio ApS Pharmaceuticals: MajorHealth Technology Draupnir Bio ApS engages in the manufacture and distribution of biotechnological and pharmaceutical products. It also provides medical research services. The company was founded on April 4, 2017 and is headquartered in Risskov, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
Ambagon Therapeutics, Inc.
Ambagon Therapeutics, Inc. BiotechnologyHealth Technology Ambagon Therapeutics, Inc. provides healthcare services. It specializes in biotechnology. The company is headquartered in San Francisco, CA. | Biotechnology | Director/Board Member | |
F-STAR THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
ACHILLES THERAPEUTICS PLC | Pharmaceuticals: Major | Chief Executive Officer Director of Finance/CFO | |
ONWARD MEDICAL N.V. | Miscellaneous Commercial Services | Director/Board Member | |
PALISADE BIO, INC. | Pharmaceuticals: Major | Director/Board Member | |
Vaximm AG
Vaximm AG Miscellaneous Commercial ServicesCommercial Services Vaximm AG provides active immunotherapies for patients suffering from cancer. It develops and provides vaccines for patients suffering from cancer. The firmalso provides research, development, manufacture, marketing and sale of pharmaceutical products. The company was founded in September 2008 and is headquartered in Basel, Switzerland. | Miscellaneous Commercial Services | Director/Board Member | |
ACERAGEN, INC. | Biotechnology | Director/Board Member |
Statistiche
Distribuzione geografica
Regno Unito | 19 |
Stati Uniti | 13 |
Paesi Bassi | 8 |
Svizzera | 7 |
Francia | 3 |
Settori
Health Technology | 26 |
Finance | 14 |
Consumer Services | 5 |
Commercial Services | 5 |
Producer Manufacturing | 2 |
Posizioni
Director/Board Member | 167 |
Corporate Officer/Principal | 69 |
Independent Dir/Board Member | 45 |
Chairman | 40 |
Chief Executive Officer | 27 |
Contatti più connessi
Insiders | |
---|---|
Julie Cherrington | 32 |
Ken Galbraith | 30 |
Roel Bulthuis | 29 |
John Bradshaw | 27 |
Cristina Csimma | 21 |
Nigel Keen | 19 |
Dominic Clive Jones | 18 |
Melanie Gee | 15 |
Anne Prener | 14 |
Virginia Holmes | 14 |
Ellen Strahlman | 14 |
Christopher David Barling | 12 |
Jeremy Tigue | 10 |
Iraj Ali | 10 |
Kemal Malik | 10 |
- Borsa valori
- Insiders
- Robert A. Hutchinson
- Connessioni Società